SCHEMBL1461981

SCHEMBL1461981

CCCCOC(=O)NC(C(=O)O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.60
SMN1; SMN2 Q16637 5/20 0.56
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
LMNA P02545 1/20 0.56
CTSK P43235 2/20 0.50
POLB P06746 1/20 0.50
CTSL P07711 1/20 0.49
CTSS P25774 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HPGD P15428 1/20 0.49
MAPK1 P28482 1/20 0.48
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
FAAH O00519 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11491274 1.00 ATM (0.60) ATMSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL1553456 0.89 FOLH1 (0.51) ATMSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL4685821 0.87 ATM (0.63) ATMSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL4686341 0.86 SMN1; SMN2 (0.60) ATMSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL3644580 0.86 L3MBTL1 (0.52) ATMSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL4597773 0.86 EPHX2 (0.48) ATMSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL13387483 0.85 SMN1; SMN2 (0.65) SMN1; SMN2NPC1RAB9ALMNACTSK
SCHEMBL13506655 0.85 NPSR1 (0.58) SMN1; SMN2NPC1RAB9ALMNACTSK
SCHEMBL1200736 0.84 ATM (0.62) ATMSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL1200738 0.84 ATM (0.62) ATMSMN1; SMN2NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104592163-A Synthetic method of chiral 2-phenylpyrrolidine ASTATECH CHENGDU BIOPHARM CO LTD 2015-05-06 CN disclosed
EP-2475665-A1 [1,2,4]TRIAZOLO [1,5-c]PYRIMIDINE DERIVATIVES AS Hsup90 MODULATORS Nerviano Medical Sciences S.r.l. (IT) 2012-07-18 EP disclosed
WO-2011029775-A1 [1,2,4]TRIAZOLO [1,5-c]PYRIMIDINE DERIVATIVES AS Hsup90 MODULATORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-03-17 WO disclosed
EP-2188276-A1 SUBSTITUTED HYDANTOINS F. Hoffmann-Roche AG (CH) 2010-05-26 EP disclosed
WO-2009021887-A1 SUBSTITUTED HYDANTOINS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-19 WO disclosed
EP-1989186-A1 HYDANTOIN BASED KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-11-12 EP disclosed
WO-2008101840-A1 COMBINATION OF ERLOTINIB AND MEK-INHIBITORS FOR INHIBITING PROLIFERATION OF TUMOR CELLS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-28 WO disclosed
EP-1924265-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS Genzyme Corporation (US) 2008-05-28 EP disclosed
WO-2007096259-A1 HYDANTOIN BASED KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-30 WO disclosed
EP-1791837-A1 SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER F. Hoffmann-Roche AG (CH) 2007-06-06 EP disclosed
WO-2007022371-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORPORATION (US) 2007-02-22 WO disclosed
WO-2006029862-A1 SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2006-03-23 WO disclosed